1-20 of 46
Vincent Levy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Tavernier Magali, Stéphane Morisset, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos Weil, Veronique Leblond, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valerie Rouillé, Alain Jacques Delmer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3268.
https://doi.org/10.1182/blood-2023-173341
Published: 2023
Journal Articles

Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia

Vincent Levy, Tushar Srivastava, Keri Yang, Palash Purkayastha, Raju Gautam, Kaijun Wang, Leyla Mohseninejad
Journal: Blood
Blood (2023) 142 (Supplement 1): 1909.
https://doi.org/10.1182/blood-2023-173540
Published: 2023
Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Christelle Portois, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean-Pierre Vilque, Therese Aurran Schleinitz, Cymbalista Florence, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen Khac, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 7013–7015.
https://doi.org/10.1182/blood-2022-157963
Published: 2022
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet
Journal: Blood
Blood (2022) 140 (Supplement 1): 7007–7009.
https://doi.org/10.1182/blood-2022-159678
Published: 2022
Journal Articles

Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study

Loic Ysebaert, Xavier Troussard, Vincent Levy, Ronan Le Calloch, Romain Guieze, Kamel Laribi, Stephane Lepretre, Anne-Sophie Michallet, Véronique Leblond, Pierre Feugier, Elhem Lahjibi, Julien Ramier, Alain Delmer
Journal: Blood
Blood (2022) 140 (Supplement 1): 12395–12396.
https://doi.org/10.1182/blood-2022-162319
Published: 2022
Journal Articles

Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)

Sylvain Choquet, Marine Deslandes, Nahid Macher, Gérard De Pouvourville, Clarisse Marchal, Manon Belhassen, Flore Jacoud, Vincent Levy
Journal: Blood
Blood (2022) 140 (Supplement 1): 9898–9899.
https://doi.org/10.1182/blood-2022-162213
Published: 2022
Journal Articles

Clinical Research in Western Africa: Efficacy and Safety of a Phase II Study of R-CHOP in First-Line DLBCL in Senegal

Saliou Diop, Sr., Charline Moulin, Sokhna Aïssatou Touré, Mourtalla Gueye, Sabine Deltour, Yankhoba Diop, Fatou Samba Ndiaye, Mouhamadou Cherif Dial, Hervé Sartelet, Moussa Seck, Seynabou Fall, Alioune Badara Senghor, Awa Oumar Touré, Blaise Felix Faye, Elimane Seydi Bousso, Alioune Badara Diallo, Mohamed Keita, Elhadji Daouda Niang, Nata Dieng, Elsa Aboud, Catherine Thieblemont, Vincent Lévy, Marie C Béné, Julien Broséus, Martine Raphael, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 9489–9490.
https://doi.org/10.1182/blood-2022-163452
Published: 2022
Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer
Journal: Blood
Blood (2022) 140 (Supplement 1): 7030–7031.
https://doi.org/10.1182/blood-2022-163096
Published: 2022
Journal Articles

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Cristina Bagacean, Rémi Letestu, Chadi Al Nawakil, Ségolène Brichler, Vincent Lévy, Nanthara Sritharan, Alain Delmer, Caroline Dartigeas, Véronique Leblond, Damien Roos-Weil, Marie C Béné, Aline Clavert, Driss Chaoui, Philippe Genet, Romain Guieze, Kamel Laribi, Yamina Touileb, Bernard Drenou, Lise Willems, Cécile Tomowiak, Fatiha Merabet, Christian Puppink, Hugo Legendre, Xavier Troussard, Stéphanie Malartre, Florence Cymbalista, Anne-Sophie Michallet
Journal: Blood
Blood (2021) 138 (Supplement 1): 637.
https://doi.org/10.1182/blood-2021-152515
Published: 2021
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, Alain Delmer
Journal: Blood
Blood (2021) 138 (Supplement 1): 641.
https://doi.org/10.1182/blood-2021-145624
Published: 2021
Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations Brief Report
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Malgorzata Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stéphane Lepretre, Vincent Levy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood
Blood (2021) 137 (8): 1019–1023.
https://doi.org/10.1182/blood.2020008164
Published: 2021
Includes: Supplemental data
Journal Articles

Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France

Honghao Fang, Harinala Ravonimbola, Nisha C Hazra, Zhou Zhou, MS, Beenish S. Manzoor, PhD MPH, Vincent Levy, MD PhD, Loic Ysebaert, MD PhD, Nathanael Kabore, Kavita Sail
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-137034
Published: 2020
Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, MD, Gilles A. Salles, MD PhD, Olivier Tournilhac, Alain Jacques Delmer, MD PhD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, MD PhD, Loic Ysebaert, MD PhD, Caroline Dartigeas, MD, Margot Truchan, Jean Pierre Vilque, Thérèse Aurran, MD, Florence Cymbalista, MD PhD, Stephane Lepretre, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3038.
https://doi.org/10.1182/blood-2019-126720
Published: 2019
Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Jérôme Paillassa, MD, Edouard Cornet, MD, Stephanie Noel, Cecile Tomowiak, Aline Schmidt, MD, Stephane Lepretre, Sandrine Vaudaux, Jehan Dupuis, MD, Alain Devidas, MD, Joly Bertrand, MD, Charlotte Petitditdier, MD, Stéphanie Haiat, Clara Mariette, MD, Catherine Thieblemont, MD PhD, Didier Decaudin, Bernard Drenou, MD, Jean Claude Eisenmann, MD, Mario Ojeda, MD, Agnès Olivrie, MD, Marie-Pierre Gourin, Olivier Lambotte, Olivier Hermine, MD PhD, Jean Michel Karsenti, MD, Pierre Feugier, MD PhD, Willy Vaillant, Jean Gutnecht, MD, Eric Lippert, MD PhD, Fabienne Huysman, MD, Kamel Ghomari, Marouane Boubaya, PhD, Vincent Levy, MD PhD, Jérémie Riou, PhD, Gandhi Damaj, MD PhD, Mathilde Hunault, MD PhD, Xavier Troussard, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1537.
https://doi.org/10.1182/blood-2019-127560
Published: 2019
Journal Articles

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Brief Report
Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier, Damien Roos-Weil, Lise Willems, Anne-Sophie Michallet, Alain Delmer, Katia Hormigos, Vincent Levy, Florence Cymbalista, Fanny Baran-Marszak
Journal: Blood
Blood (2019) 134 (7): 641–644.
https://doi.org/10.1182/blood.2019000854
Published: 2019
Includes: Supplemental data
Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Véronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier
Journal: Blood
Blood (2018) 132 (Supplement 1): 1858.
https://doi.org/10.1182/blood-2018-99-111977
Published: 2018
Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 584.
https://doi.org/10.1182/blood-2018-99-114027
Published: 2018
Journal Articles

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

Sophie Godet, MD, Anne Quinquenel, Caroline Dartigeas, MD, Loic Ysebaert, MD PhD, Jehan Dupuis, MD, Haykanush Ohanyan, Aude Collignon, Laurent Gilardin, MD MSc, Stéphane Leprêtre, MD, Marie-Sarah Dilhuydy, MD, Marguerite Vignon, MD, Sophie de Guibert, MD, Natalia Dmytruk, MD, Eric Durot, MD, David Ghez, MD PhD, Damien Roos-Weil, MD, Elise Toussaint, MD, Fatiha Merabet, MD, Vincent Levy, MD PhD, Alain Jacques Delmer, MD, Thérèse Aurran, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3152.
https://doi.org/10.1182/blood-2018-99-112654
Published: 2018
Journal Articles

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, Cecile Tomowiak, MD, Sophie de Guibert, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen Khac, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 497.
https://doi.org/10.1182/blood.V130.Suppl_1.497.497
Published: 2017
Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Fanny Baran-Marszak, MD PhD, Valerie Vidal, Myriam Hormi, Virginie Eclache, Lauren Veronese, MD PhD, Olivier Tournilhac, MD PhD, Frederic Davi, Florence Nguyen-Khac, MD PhD, Veronique Leblond, Eric Delabesse, MD PhD, Loic Ysebaert, MD PhD, Audrey Bidet, PharmD, Marie-Sarah Dilhuydy, MD, Stephanie Poulain, MD PhD, Charles Herbaux, Marie-Helene Estienne, PharmD, Caroline Dartigeas, Cedric Pastoret, MD, Sophie de Guibert, Stephane Giraudier, MD PhD, Jehan Dupuis, MD, Pascale Cornillet-Lefebvre, Anne Quinquenel, Sophy Laibe, Thérèse Aurran, MD, Dina Naguib, MD MASTERS, Xavier Troussard, MD, Pierre Sujobert, MD PhD, Anne-Sophie Michallet, MD PhD, Catherine Thieblemont, MD PhD, Remi Letestu, Gregory Lazarian, PharmD, Vincent Levy, MD PhD, Thierry Soussi, Sophie Raynaud, MD PhD, Florence Cymbalista, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1722.
https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722
Published: 2017